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Summary
Intracellular proteins are degraded in the antigen pro-
cessing pathway to generate peptide-loaded MHC I
complexes (pMHC I) for immune surveillance. The
characteristics of the final pMHC I are clear but those
of their precursors and their potential binding partners
remainpoorlydefined.Byusingauniquemethod tobio-
chemically detect preprocessed ovalbumin-derived
antigenic peptides, we find that cells generate large,
C-terminally extended proteolytic intermediates that
are associated with the a isotype of hsp90 chaperone.
Knockdownofhsp90aexpressionbysiRNAresulted in
the loss of these intermediates and decreased presen-
tationof thefinalpMHC Ion thecell surface.Generation
of pMHC I was also inhibited by knockdown of the
cochaperone CHIP that interacts with heat shock pro-
teins, ubiquitinates their clients, and delivers them to
the proteasome. Thus, hsp90a can serve as a chaper-
one for precursors of pMHC I at an early stage in the
antigen processing pathway.
Introduction
Immune surveillance by CD8 T cells depends upon the
ability of target cells to display processed peptides
bound to MHC I molecules on their surface (Shastri
et al., 2002, 2005). The peptides are derived from normal
self as well as foreign proteins that arise in cells as
a consequence of viral or bacterial infection, mutations
in tumor cells, or polymorphisms in histocompatibility
loci. With exquisite sensitivity, CD8 T cells can detect
novel peptides that are present within the thousands of
other peptides displayed by the MHC I molecules on
the cell surface and cause target cell lysis. These
pMHC I molecules are generated by the antigen process-
ing pathway.
Successful loading of MHC I molecules depends upon
generating both the peptide-receptive MHC molecules in
the endoplasmic reticulum (ER) and a diverse pool of
processed peptides in the cytoplasm (Cresswell et al.,
1999). The cytoplasmic peptide pool is brought into the
ER via the transporters associated with antigen process-
ing (TAP) (Androlowicz and Cresswell, 1996). Most pep-
tides that arrive in the ER not only have precise C termini
generated by cytoplasmic proteases but also contain
additional N-terminal flanking residues (Cascio et al.,
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moving the extra N-terminal residues has now been iden-
tified by the recent discovery of the ERAAP/ERAP1 ami-
nopeptidase that operates in the ER and is involved in the
generation of the final pMHC I complex (Serwold et al.,
2002; York et al., 2002; Hammer et al., 2006).
What transpires in the cytoplasm where the antigen
processing pathway begins is far less certain. It is clear
that antigen processing largely depends upon activity of
the multicatalytic proteasome and in some cases the tri-
peptidyl protease (TPPII) or other cytoplasmic prote-
ases (Kloetzel, 2004). But the nature of their substrates
or products in living cells has remained elusive. Further-
more, it has been suspected for some time that the pro-
teolytic intermediates are bound to cellular chaperones,
but the significance of these interactions in the antigen
processing pathway is unclear (Srivastava, 2002). As
a result, the molecular mechanism for the immuno-
genicity of the peptide cargo carried by cytoplasmic and
ER chaperones has remained uncertain (Binder and
Srivastava, 2005).
These uncertainties in the early steps in the antigen
processing pathway result from a lack of methods to
detect proteolytic intermediates. Virtually all methods,
whether they rely on activation of specific T cells or the
binding of antibodies to specific pMHC I complexes,
cannot detect the antigenic peptides when they are not
bound to MHC molecules. The pioneering analysis by
the Rammensee group allowed biochemical detection
of naturally processed peptides in cell extracts and re-
vealed the nature of the final peptides bound to MHC I
(Ro¨tzschke et al., 1990; Rammensee et al., 1993). It has
since been clear that MHC I molecules present peptides
with precise N- and C termini that share consensus se-
quence motifs defined by length and conserved anchor
residues (Falk et al., 1991). However, even this method
is not sensitive enough to detect proteolytic intermedi-
ates when they contain additional residues flanking the
final antigenic peptide. And the fate of synthetic peptides
examined in cells by following their fluorescent tags may
be distinct from that of natural precursors and their inter-
mediates generated during antigen processing in cells
(Reits et al., 2004).
To overcome these profound sensitivity limits, we
have devised unique methods for detecting proteolytic
intermediates that are generated during normal antigen
processing in living cells (Paz et al., 1999; Serwold and
Shastri, 1999; Kunisawa and Shastri, 2003). The analysis
of small <10 kDa peptides in cell extracts revealed that
the model antigen ovalbumin was fragmented into a
mixture of intermediates that all contained the final an-
tigenic SIINFEHL (SHL8) peptide with only N-terminal
flanking residues (Kunisawa and Shastri, 2003). Further-
more, some of these peptides were found to be associ-
ated with the group II chaperonin TRiC/CCT. However,
whether these small N-terminally extended intermedi-
ates were generated directly from their full-length pre-
cursor or yet other intermediates was not established.
Here, we analyzed large proteolytic intermediates in
living cells. We find that large proteolytic intermediates
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minal flanking residues also exist in the antigen process-
ing pathway. Most interestingly, the fate of these inter-
mediates and presentation of the final pMHC I on the
cell surface depends upon the presence and function
of the a isotype of the cytoplasmic chaperone hsp90.
Results
Biochemical Methods for Detecting Proteolytic
Intermediates in the Antigen Processing Pathway
We used biochemical methods developed to detect pro-
teolytic intermediates in the MHC I antigen processing
pathway (Paz et al., 1999; Kunisawa and Shastri, 2003).
These assays take advantage of the fact that CD8 T cells
can recognize their cognate antigenic peptide with high
sensitivity in the picomolar concentration range. How-
ever, this conventional assay is not sensitive enough to
detect antigenic peptides when they are embedded
within larger peptides containing additional amino and/
or carboxy-terminal flanking residues (Kunisawa and
Shastri, 2003). We reasoned that if the residues flanking
the antigenic peptide could be precisely removed prior
to their assay this would improve the sensitivity of the as-
say to the otherwise undetectable proteolytic inter-
mediates (Figure 1). This was accomplished by making
several key modifications in the precursor protein se-
quence and by using well-characterized proteases to
make the appropriate N- and C-terminal cuts. First, we
changed the internal lysine residue within ovalbumin
(OVA)-derived SIINFEKL peptide, which is presented
by the Kb MHC molecule to the B3Z T cells to a histidine
residue SIINFEHL (SHL8) to make the antigenic peptide
refractory to trypsin without altering its antigenicity
(Paz et al., 1999). Second, we mutagenized the OVA se-
quence by placing two lysine residues at the amino and
carboxyl termini of the SHL8 peptide. These changes al-
low the release of the SHL8 peptide from any potential
precursor by using trypsin that cleaves at the lysine res-
idues and carboxypeptidase B (CPB) that cleaves the
C-terminal lysine residue. Third, we removed the N-ter-
minal ER targeting signal in native OVA to constrain the
expression of the precursor to the cytoplasm. We refer
to this model as ‘‘KOVAK’’ to indicate the presence of
the two key lysine (K) residues that flank the final peptide
within the OVA precursor. Similar to native OVA that is
processed to the SIINFEKL peptide, the KOVAK precur-
sor is also processed to the precisely cleaved SIINFEHL
(SHL8) peptide in Kb expressing cells in a proteasome
and TAP-dependent manner (Paz et al., 1999; Kunisawa
and Shastri, 2003). However, unlike native OVA whose
naturally processed intermediates cannot be detected
in cell extracts, the KOVAK model permits their analysis
(Figure 1).
We first fractionate the filtered cell extracts by reverse-
phase HPLC to separate the naturally processed interme-
diates according to their hydrophobicity, which is directly
proportional to their size. The embedded SHL8 peptide in
each fragment is then released by treating the fractions
with trypsin alone or with trypsin plus CPB. The SHL8
peptide in the fractions is then assayed by using the
SHL8/Kb-specific B3Z T cell hybridoma and Kb express-
ing L cells as APC. Thus, it is possible to biochemically
detect and characterize any proteolytic intermediate(s)that may be generated in the living cells during antigen
processing events (Figure 1). Note that the KOVAK model
allows us to also determine if any antigenic fragments in
the cell extracts contained only N-terminal flanking resi-
dues (N+ peptides) because they can be detected after
trypsin treatment alone or contained N- and/or C-terminal
flanking sequences (C+ and/or N+C+), which can be
detected only after treatment with trypsin plus CPB.
To examine whether proteolytic intermediates gener-
ated during antigen processing had the N+ and/or C+ ex-
tensions, we extracted peptides from stable HeLa cell
transfectants expressing the KOVAK precursor (HeLa/
KOVAK). Normally, the cell extract is passed through
a 10 kDa molecular weight filter to remove large molecu-
lar weight material and to collect only the small peptides
in the filtrate. The <10 kDa filtrate was fractionated by re-
verse-phase HPLC, and potential B3Z stimulating anti-
genic peptides were detected after treating the fractions
with trypsin alone or with trypsin plus CPB. As seen in our
previous study, this method revealed the presence of six
to eight distinct peaks of antigenic activity when the frac-
tions were treated only with trypsin prior to the B3Z assay
(Figure 2A). These peaks therefore represent a set of N+
peptides. Four of these peaks could be assigned to spe-
cific N-terminally extended peptides (e.g., QLK-[SHL8]
and LEQLK-[SHL8]) based on the elution times of the
synthetic peptides run under identical conditions. Note
that the final SHL8 peptide is barely detectable in the
extracts because its accumulation requires the presence
Figure 1. Schematic Illustration of the KOVAK Model for Detecting
Potential Antigenic Intermediates Containing the Antigenic Peptide
and Additional N- and/or C-Terminal Residues
The KOVAK precursor was generated by deleting the ER translocation
signal of the wild-type ovalbumin to constrain its expression in the cy-
toplasm and by placing lysine (K) residues at both the N- and C-termi-
nal flanking positions of the antigenic peptide SHL8 (). The potential
processing intermediates that could arise in cells are depicted as the
antigenic SHL8 peptide () with varying numbers of N- and/or C-termi-
nal flanking residues shown as ‘‘w.’’ Expression of both the KOVAK
precursor and the Kb MHC I resulted in the generation of the final
SHL8/Kb complex on the cell surface that is recognized by B3Z T cells.
In cells without Kb MHC, the intermediates are detected after treat-
ment of HPLC-fractionated cell extracts with either trypsin alone
(N+ peptides) or trypsin plus CPB (C+ or N+C+ peptides), which cause
release of the SHL8 peptide (). The optimally active SHL8 peptide is
detected by B3Z T cells in presence of Kb expressing APCs.
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(A–D) Peptides were extracted from 53 106 HeLa/KOVAK cells and fractionated over a 10 kDa (A and B) or a 30 kDa (C and D) molecular weight
filter. The filtrate was fractionated by reverse-phase HPLC. The antigenic peptides in each fraction were assayed by their ability to stimulate B3Z
T cells in the presence of Kb-L cells as APC. Prior to the B3Z T cell assay, each HPLC fraction was treated with trypsin alone (A and C, black line) or
with trypsin plus CPB (A and C, red line). The relative amounts indicate the SHL8 activity in the different HPLC peaks detected after treatment of
fractions with trypsin alone (open bars) or trypsin plus CPB (red bars) (B and D).
(E and F) SHL8 containing intermediates in HeLa/KOVAK cells after overnight treatment with the proteasome inhibitor MG132 (E) or serine
protease (e.g., TPPII) inhibitor AAF-CMK (F). The <30 kDa material was separated by HPLC, and each fraction was assayed after trypsin plus
CPB treatment as in (C). B3Z response was measured as the induced b-galactosidase activity, which converts the substrate chlorophenol
red b-pyranoside to the chlorophenol red product that absorbs light at 595 nm wavelength. Up or down arrows indicate an increase or decrease
in the antigenic peptides relative to mock-treated controls. Data shown are representative of three independent experiments.of the Kb molecule, which is not expressed by the human
HeLa cells (Falk et al., 1993; Paz et al., 1999). Signifi-
cantly, a similar set of activity peaks was detected
when the same <10 kDa fractions were treated with tryp-
sin plus CPB (Figure 2A), with little difference in their
relative amounts (Figure 2B). Thus, at steady-state con-
ditions, the cells contain predominantly N-terminally
extended SHL8 intermediates (N+ peptides) in the <10kDa fraction and C-terminally extended analogs were
not detected. Thus, proteolytic processes generate the
precise C terminus of the antigenic SHL8 peptide with
high efficiency.
The KOVAK precursor contains 249 residues with a pre-
dicted size of 27 kDa. To determine whether KOVAK was
directly cleaved into the set of N+ peptides detected in
the <10 kDa fraction or whether there were yet larger
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cell extracts through a 30 kDa molecular weight filter. The
<30 kDa filtrate was fractionated over the same HPLC col-
umn, and the fractions were analyzed for the presence of
N+ peptides after treatment of each fraction with trypsin
alone. Three new peptide peaks were detected in frac-
tions 60 and 81–86, demonstrating the existence of larger
10–30 kDa N+ fragments (Figure 2C, black line). Remark-
ably, when the same fractions were analyzed after treat-
ment with trypsin plus CPB, more new peaks were de-
tected in later fractions 87–106 (Figure 2C, red line).
Comparison of the relative amount of antigenic peptides
in the <30 kDa material detected with trypsin alone versus
trypsin plus CPB showed that the peptides that were de-
tected only after trypsin plus CPB treatment (C+/N+C+
peptides) were predominantly located in fractions 87–
90, 91–96, and 102–106 (Figure 2D). We do not yet know
the precise identity of these late eluting peptides, but
theyare 10–30 kDa insizebecause theywerenot detected
in the <10 kDa material (Figure 2A). Furthermore, because
they were detected only after the fractions were treated
with trypsin plusCPB shows that these intermediates rep-
resent larger C+ and/or N+C+ peptides and the N+C+ pep-
tides could serve as the precursors for the N+ intermedi-
ates after removal of the C-terminal residues flanking
the SHL8 peptide.
The mechanisms that generate this mixture of 10–30
kDa proteolytic fragments are presently unclear. It is pos-
sible that these polypeptides may have been synthesized
directly as defective ribosomal products (DRiPs) that are
believed to be the principle substrates for antigen pro-
cessing (Yewdell et al., 2003) or they might have resulted
from proteolysis of the full-length KOVAK precursor. To
determine whether the generation of these antigenic pep-
tides required the multicatalyticproteasome, weanalyzed
extractsofcells treated withMG132,a potentproteasome
inhibitor (Rock et al., 1994). Compared to the extracts
from untreated cells (Figure 2C), MG132-treated cells
showed a remarkable increase in the peaks eluting in
the late HPLC fractions 60–106 (Figure 2E, arrows). The in-
crease in antigenic activities was particularly pronounced
among peptides that eluted in later fractions 66–88, 70–
72, 74–76, and the yet larger peptides that eluted in frac-
tions 91–96, 97–100, and 102–106 (Figure 2E). Because
these peptides are detected only after trypsin plus CPB
(Figure 2C), we conclude that they represent the set of
C+/N+C+ peptides and are proteasomal substrates.
Recently, tripeptidyl peptidase II (TPPII) that pos-
sesses endopeptidase as well as exopeptidase activity
has also been implicated in the antigen processing path-
way (Geier et al., 1999; Seifert et al., 2003; Kloetzel, 2004).
To test the potential role of TPPII in processing KOVAK,
we analyzed extracts of cells treated with the AAF-CMK,
a general inhibitor of serine proteases, including TPPII. In
contrast to MG132-treated cells, AAF-CMK-treated cells
contained a qualitatively and quantitatively different pat-
tern of antigenic peptides (Figure 2F). Antigenic peptides
increased in fractions 92–106 and decreased in fractions
53–62 and 80–88, suggesting a potential precursor/prod-
uct relationship. Note that all fractions with reduced
activity contained only smaller <10 kDa N+ peptides,
whereas those with increased activity were larger
10–30 kDa C+/N+C+ peptides. Thus, AAF-CMK-sensitive
proteases, which include TPPII, can also generate thecorrect C terminus of the final SHL8 peptide. Neverthe-
less, compared to AAF-CMK, treatment with MG-132
consistently resulted in quantitatively higher accumula-
tion of the N+C+ set of peptides, suggesting that they
were predominantly proteasomal substrates.
Regardless of the particular proteases involved our
analysis of the smaller <10 kDa and the larger 10–30
kDa material in cell extracts shows unambiguously that
cells expressing the KOVAK precursor generated short
N+ as well as large C+/N+C+ proteolytic intermediates.
C+/N+C+ Proteolytic Intermediates Associate
with the a Isotype of Hsp90
We had previously determined that the antigenic inter-
mediates in the cell extracts were not free but were asso-
ciated with high molecular weight proteins (Paz et al.,
1999). Furthermore, we had identified the group II chap-
eronin TRiC/CCT as a chaperone for several N-terminally
extended N+ peptides in the <10 kDa fraction by coim-
munoprecipitation and TRiC knockdown experiments
(Kunisawa and Shastri, 2003). Curiously, despite earlier
reports of hsp90-associated antigenic activities (Ishii
et al., 1999), and the presence of hsp90 in the fractions
that contained antigenic activity in size-fractionated
cell extracts, no antigenic peptides were detected in
the <10 kDa material associated with hsp90 in our previ-
ous study (Kunisawa and Shastri, 2003). With the discov-
ery of the 10–30 kDa proteolytic intermediates, we re-
examined the hsp90 immunoprecipitated material in
the <30 kDa filtrates. Western blot analysis showed
that hsp90 was immunoprecipitated from total cell ex-
tracts with specific rabbit polyclonal antiserum, but not
by normal rabbit serum (Figure 3A). The immunoprecip-
itated material was acid extracted to collect the associ-
ated material and was then filtered through a 30 kDa
filter. The filtrate from the material immunoprecipitated
by hsp90-specific antibody contained B3Z-stimulating
activity, whereas no activity was detected in the material
immunoprecipitated by control rabbit serum (Figure 3B).
Furthermore, when hsp90 was immunoprecipitated from
cells treated with geldanamycin, a potent hsp90 inhibitor
(Picard, 2002), the B3Z stimulating activity fell dramati-
cally despite no change in the total amount of hsp90 in
the treated cells (Figures 3A and 3B). These results indi-
cate that hsp90 may associate directly or indirectly with
antigenic intermediates derived from the KOVAK precur-
sor, and this association is geldanamycin sensitive. To
determine which intermediates were associated with
hsp90, the filtrate was fractionated by HPLC and the frac-
tions were assayed for presence of antigenic activities
using trypsin alone or trypsin plus CPB. No antigenic
activity of N+ peptides was detected in the fractions after
treatment with trypsin alone (Figure 3C). In contrast, with
trypsin plus CPB treatment of the same fractions, three
distinct peaks of antigenic activity were detected
(Figure 3D). Note that the same peaks (fractions 86–88,
91–94, and 102–106) were also identified in total cell ex-
tracts to contain C+/N+C+ intermediates only after trypsin
plus CPB treatment (Figure 2C). Thus, despite the pres-
ence of at least 13 different small N+ and larger C+/
N+C+ fragments in the cells, only the largest N+C+ frag-
ments were associated with hsp90.
The hsp90 protein is expressed as two closely re-
lated isotypes, hsp90a and hsp90b, in humans, mice,
Chaperones in the MHC I Antigen Processing Pathway
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Hsp90 with N- and C-Terminally Extended
Antigenic Intermediates
(A) The material immunoprecipitates with ei-
ther anti-hsp90 antibody or the control rabbit
serum from HeLa/KOVAK cells treated with
or without 10 mM geldanamycin were ana-
lyzed by Western blotting with hsp90-specific
antibody.
(B) The immunoprecipitates from mock-
treated HeLa/KOVAK cells with either anti-
hsp90 antibody (B) or the control rabbit se-
rum (:), or from geldanamycin-treated
HeLa/KOVAK cells with anti-hsp90 antibody
(d) were acid extracted to dissociate pep-
tides. The <30 kDa filtrate dried and was re-
suspended in PBS, and the indicated dilu-
tions were treated with trypsin plus CPB and
tested for B3Z stimulating activity.
(C and D) The immunoprecipitates with either
anti-hsp90 antibody (d) or the control rabbit
serum (B) were acid extracted to dissociate
peptides. The <30 kDa filtrate was fraction-
ated by HPLC followed by treatment with
trypsin alone (C) or trypsin plus CPB (D) be-
fore the B3Z assay.
(E and F) Hsp90a (E) or hsp90b (F) was immu-
noprecipitated from the lysates of HeLa/KO-
VAK cells, and B3Z assay was performed as
in Figure 2. Each experiment was repeated
three times.Drosophila, and yeast (Rebbe et al., 1987; Moore et al.,
1989). The two isotypes are generally referred to in the lit-
erature simply as hsp90 because both proteins are ubiq-
uitously expressed and they cannot be distinguished in
assays for chaperone functions or by the pharmaco-
logical inhibitors geldanamycin or radicicol (Whitesell
et al., 1994; Sharma et al., 1998). To determine if the inter-
mediates detected in the total hsp90 immunoprecipitate
could be assigned to a particular hsp90 isotype, we used
antibodies to individually immunoprecipitate hsp90a or
hsp90b. Analysis of the associated antigenic activities
in the <30 kDa filtrate showed that the same three distinct
C+/N+C+ activity peaks found in the total hsp90 immuno-
precipitate were also present in the hsp90a (Figure 3E)
but were not detected in the hsp90b immunoprecipitates
(Figure 3F). Thus, despite comparable chaperone acti-
vity toward other substrates, only hsp90a, and not
hsp90b, was associated with the C-terminally extended
antigenic intermediates.
Knockdown of Hsp90a Isotype Slows Cell Division
but Does Not Affect Viability and Protein Synthesis
To further evaluate the biological function of hsp90
isotypes, we knocked down their expression by using
small interfering RNA (siRNA). Because the two hsp90 iso-
types are encoded by different genes, we designed siRNAoligonucleotides specific for hsp90a or hsp90b mRNAs.
As a negative control, we used siRNA specific for the neo-
mycin phosphotransferase (Neo), which was used as the
G418 drug selection marker to generate the HeLa/KOVAK
transfectants. After transfecting the cells with each pair of
siRNAs, we determined the expression of hsp90a and
hsp90b isotypes as well as other cellular chaperones
and actin by Western blotting serial dilutions of cell ex-
tracts (Figure 4A). In cells treated with siRNA specific for
hsp90b, its expressionwas undetectable, whereas the ex-
pression of the other proteins tested, including hsp90a,
remained intact. In contrast, treatment with hsp90a-spe-
cific siRNA showed that the amount of hsp90a was re-
duced byw50%. However, when the cells were treated
with siRNA specific for both hsp90a and hsp90b
(hsp90a+b), hsp90a expression was further reduced by
about 70%–80% compared to control cells treated with
Neo siRNA. Treatment of cells with either siRNA did not al-
ter the expression of closely related hsp90 homolog lo-
cated in the ER (gp96), or the other cytosolic chaperones
(hsc70, TRiCa) or actin (Figure 4A). We conclude that
siRNA treatment specifically knocked down expression
of the hsp90 isotypes while leaving expression of other
heat shock proteins as well as actin unchanged.
We next assessed the effects of hsp90 knockdown
on cell viability. Although the amount of hsp90b was
Immunity
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(A) The indicated dilutions of the whole-cell lysates of HeLa/KOVAK cells transfected with siRNA targeted to the Neo, hsp90a, hsp90b, or
hsp90a+b transcripts were fractionated by SDS-PAGE and Western blotted with the indicated antibodies.
(B) Cell numbers were determined after 4 days of culture following transfection of 13 105 cells with siRNA targeted to Neo, hsp90a, hsp90b, or
hsp90a+b mRNA. The bars represent an average 6 SD of six independent experiments.
(C) HeLa/KOVAK cells were transfected with siRNA targeted to the Neo, hsp90a, hsp90b, or hsp90a+b transcripts and were stained with DNA
binding dye propidium iodide (PI) and analyzed by flow cytometry.
(D) Newly synthesized proteins were labeled with 35S-Met/Cys and separated by 10% SDS-PAGE. The labeled proteins were detected by expos-
ing the gel to X-ray film. Similar results were obtained in two independent experiments.profoundly inhibited (Figure 4A), there was no significant
difference in number of cells in culture after Neo or
hsp90bsiRNA treatments (Figure 4B). In contrast, knock-
down of hsp90a resulted in w50% reduction in cells in
the cultures compared to the Neo control (Figure 4B).
The number of cells was further reduced to w40%
when both hsp90a and hsp90b were knocked down. In
spite of the reduced numbers, the cells were viable
(>95%) as judged by trypan blue staining (data not
shown) or by flow cytometry of propidium iodide-labeled
cells (Figure 4C). Furthermore, we were also unable to
detect differences in the overall synthesis of new pro-
teins labeled by 35S-Met/Cys (Figure 4D). These results
show that loss of hsp90b expression had no detectable
effect on cell division, viability, or protein synthesis, but
hsp90a was required to maintain the normal rate of cell
division. Most importantly, even with the decrease in
the amount of hsp90a, the cells remained viable and con-
tinued to synthesize new proteins.
Knockdown of Hsp90a, but Not Hsp90b, Causes
Loss of Proteolytic Intermediates
To analyze the proteolytic intermediates in HeLa/KOVAK
cells with knocked down expression of hsp90 isotypes,
we analyzed the antigenic intermediates in <30 kDa fil-
trates of cell extracts. In contrast to the normal array of
antigenic peptides detected in the Neo inhibited controlcells, several peptide peaks were clearly reduced in
hsp90a-inhibited cells (Figures 5A and 5B). Interestingly,
the maximum reduction in the antigenic peptides oc-
curred in fractions 87–90, 91–96, and 102–106, which
were the same as those found in the hsp90a immunopre-
cipitates (Figures 3D and 3E). Again, consistent with the
absence of antigenic peptides in the hsp90b immunopre-
cipitates, knockdown of hsp90b isotype did not reduce
any of the proteolytic intermediates and actually en-
hanced some of the activity peaks. The simultaneous
knockdown of hsp90a and hsp90b showed an effect gen-
erally similar to that of hsp90a knockdown alone. Taken
together with the analysis of coimmunoprecipitation
experiments, these results provide independent support
to the idea that hsp90a associates with the C+/N+C+
proteolytic intermediates, which in the absence of
hsp90a, are likely degraded.
Knockdown of Hsp90a Expression Influences
Antigen Presentation on the Cell Surface
Next, we assessed the importance of hsp90 in the pre-
sentation of peptide-loaded MHC I molecules on the
cell surface. We examined antigen presentation in
HeLa cells that were cotransfected with the Kb MHC,
SHL8 precursor constructs to allow expression of the
SHL8/Kb complex on the cell surface (HeLa/KOVAK/
Kb). After the treatments, the cells were acid washed to
Chaperones in the MHC I Antigen Processing Pathway
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(A) Peptides were extracted from HeLa/KOVAK cells transfected with the indicated siRNA, passed through 30 kDa filter, and fractionated by
reverse-phase HPLC. B3Z T cell response to each fraction was measured after treatment with trypsin plus CPB as in Figure 2.
(B) The relative amount of SHL8 activity in each fraction of control (open), hsp90a (light gray), hsp90b (dark gray), or hsp90a+b (black) knockdown
cells is shown. The amount of antigenic activity in control Neo cells was assigned an arbitrary value of 1. The data are representative of four in-
dependent experiments.remove preexisting Kb bound peptides, and the cells
were then allowed to recover in normal medium for the in-
dicated time periods. The recovery of newly assembled
SHL8/Kb complex on the cell surface was then assessed
by using B3Z T cells. We first treated the cells with geld-
anamycin, which inhibits hsp90 function and was seen
to disrupt its association with the SHL8 intermediates
(Figure 3B). Geldanamycin treatment caused a notable
delay in the recovery of B3Z stimulating SHl8/Kb com-
plex on the surface in cells expressing the cytoplasmic
KOVAK precursor (Figure 6A). Again, consistent with
the analysis of cell extracts, both the Neo or hsp90b
knocked down cells generated the SHL8/Kb complex at
a similar rate. However, when hsp90a or hsp90a+b was
knocked down, there was a consistent delay in the re-
covery of the SHL8/Kb complex on the cell surface at
both the 6 and 10 hr time points (Figure 6B). As an inde-
pendent control, we also tested HeLa cells stably ex-
pressing the ER-targeted SHL8 (ES-SHL8) and Kb MHC
in a similar fashion. In contrast to the KOVAK precursor,
when either the Neo or hsp90b, hsp90a, or hsp90a+b
expression was knocked down in cells expressing the
ES-SHL8 precursor, there was no detectable difference
in the rate of recovery of the SHL8/Kb complex. Likewise
knockdown of hsp90a+b did not change the recovery of
a different peptide recognized by 27.5Z T cells (Fig-
ure 6D). Thus, the decrease in hsp90a expression did
not affect the ability of cells to generate processed
SHL8/Kb complexes from the ER-targeted precursor,
or the pecursor for the yet unknown peptide recognizedby 27.5Z T cells, but affected only the processing and
presentation of the cytoplasmic KOVAK precursor.
Thus, the effect of hsp90a knockdown on antigen pre-
sentation was dependent upon the antigen rather than
indirect effects on general cell physiology (Figure 6D).
We conclude that loss of proteolytic intermediates that
accompanies the knocked down hsp90a+b correlates
with decreased presentation of the final SHL8 peptide
on the cell surface.
Antigen Presentation Is Inhibited in Cells Lacking
Cochaperone CHIP
Finally, we assessed the potential role of the carboxyl
terminus of Hsc70-interacting protein (CHIP) in the anti-
gen processing pathway. The CHIP protein interacts with
the chaperones hsp90 and hsp70, and the complex
transfers the chaperone-associated clients to the ubiqui-
tin-proteasome-mediated degradation pathway via its
E3 ubiquitin ligase activity (Connell et al., 2001). To as-
sess the potential involvement of CHIP in antigen
processing, we knocked down CHIP in HeLa/KOVAK/
Kb cells and measured generation of newly synthesized
SHL8/Kb complexes after an acid wash to remove preex-
isting Kb bound peptides as described above (Figure 6).
As an additional control, we also examined the effect of
knockdown of another E3 ubiquitin ligase, mouse double
minute 2 (MDM2) (Momand et al., 1992). Western blot
analysis showed that the transfection of CHIP-specific
and MDM2-specific siRNA resulted in the effective
knockdown of CHIP and MDM2, respectively, whereas
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amount of newly generated SHL8/Kb complex on the
cell surface was then quantified by B3Z cells (Figure 7B).
The recovery of SHL8/Kb complex on the cell transfected
with CHIP-specific siRNA was significantly lower than
that of cells transfected with control Neo-specific or
MDM2-specific siRNA when KOVAK was expressed as
antigen (Figure 7B). In contrast, the recovery of the
SHL8/Kb complex on the cell surface was comparable
regardless of whether Neo or CHIP was knocked down
in the cells expressing ER-targeted SHL8 (Figure 7B).
We conclude that interference with CHIP function
inhibits the presentation of the SHL8/Kb complex that
is derived from the cytoplasmic KOVAK, but not the
ER-targeted precursors.
Discussion
The expression of the peptide bound MHC I complex on
the cell surface is the formal end of the antigen process-
ing pathway that had begun earlier in the cytoplasm and
progressed through the ER. After its assembly in the ER,
Figure 6. Antigen Presentation in Hsp90a Knockdown Cells from
Cytoplasmic or ER-Targeted Precursors
(A) HeLa/KOVAK/Kb cells were treated with 10 mM geldanamycin
overnight. The recovery of SHL8/Kb on the cell surface was deter-
mined by B3Z cells. The data are representative of three-indepen-
dent experiments.
(B and C) HeLa/KOVAK/Kb cells (B) or HeLa/ES-SHL8/Kb cells (C)
were transfected with siRNA specific for Neo (B), hsp90a (d),
hsp90b (:), or hsp90a+b (-). After 4 days, the cells were acid
washed to remove preexisting pMHC complexes and allowed to
recover in medium alone to generate new SHL8/Kb complexes. At
the indicated times, the cells were fixed with 1% paraformaldehyde
and cultured overnight with B3Z cells to assess the level of SHL8/
Kb on the cell surface. Three independent experiments showed
similar results.
(D) HeLa/KOVAK/Kb cells were transfected with siRNA specific for
Neo (B) or hsp90a+b (d). After 4 days, acid-wash/recovery assay
was used to measure the generation of the peptide/Kb complex rec-
ognized by 27.5Z cells on the cell surface 10 hr after acid treatment.
The data show mean 6 SEM from triplicate cultures and are repre-
sentative of two independent experiments.the pMHC I emerges on the cell surface where its pres-
ence can be detected by CD8 T cells or with monoclonal
antibodies specific for the pMHC I complex. Because
neither method can detect processed peptides before
they bind to MHC I, our understanding of the naturally
processed intermediates and their lifestyle during the
early phase of antigen processing is incomplete.
Here, we directly assayed proteolytic intermediates
containing the final SHL8 peptide in its preprocessed
form in cells expressing its KOVAK precursor in the
absence of the relevant Kb MHC I molecule. We used
enzymatic methods to detect the final optimally active
SHL8 peptide after it was released from N+ (with trypsin
alone) or C+/N+C+ (with trypsin plus CPB) polypeptides
containing additional N- or N- and C-terminal flanking
residues, respectively (Figure 1). In addition, we fraction-
ated the cell extracts through 10 kDa or 30 kDa filters to
estimate their size. As shown earlier, the cells contained
predominantly small N+ intermediates in the <10 kDa
fraction (Kunisawa and Shastri, 2003) but contained
large C+/N+C+ intermediates in the 10–30 kDa fraction
(Figure 2). Most significantly, the C-terminally extended
proteolytic intermediates accumulated in cells treated
with MG132 or AAF-CMK, which respectively inhibit the
proteasome or serine proteases, including TPPII (Fig-
ures 2E and 2F). This striking result suggests that the
large C+/N+C+ fragments are likely substrates for these
Figure 7. Inhibition of the Cochaperone CHIP Function Diminishes
pMHC I Generation from Cytoplasmic, but Not ER-Targeted, Precur-
sors
(A) HeLa/KOVAK/Kb cells were transfected with siRNA for Neo,
CHIP, or MDM2. After 96 hr, the diluted lysates were separated by
SDS-PAGE and probed with anti-human CHIP, anti-human MDM2,
or anti-actin antibody. The data are representative of two indepen-
dent experiments.
(B) HeLa/KOVAK/Kb cells (left) or HeLa/ES-SHL8/Kb cells (right)
were transfected with siRNA for Neo (B), CHIP (d), or MDM2 (:).
After 96 hr, the cells were acid washed and allowed to recover in
normal medium for 3, 6, or 9 hr followed by B3Z assay as in Figure 6.
The data show mean 6 SEM from triplicate cultures and are repre-
sentative of two independent experiments. The asterisk indicates
p < 0.05 compared to Neo-knocked down cells.
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the recovery of at least four N+ intermediates, which
was not observed with MG132 treatment (Figures 2E
and 2F). Furthermore, compared to MG132 treatment,
which caused accumulation of five large C+/N+C+ frag-
ments, AAF-CMK treatment caused accumulation of
only two peaks containing C+/N+C+ fragments. With the
caveat that inhibitors may also have indirecteffects, these
findings suggest that the proteasome and TPPII do not
simply compensate for each other but can serve nonover-
lapping functions as suggested by Seifert and colleagues
(Seifert et al., 2003; Kloetzel, 2004). Regardless of the
precise mechanisms that generate these fragments, our
results show unambiguously that cells contain a mixture
of large C-terminally extended fragments that can serve
as precursors for the set of smaller N+ fragments normally
present under steady-state conditions.
Interestingly, unlike the smaller N+ intermediates that
were associated with the group II chaperonin TRiC/
CCT (Kunisawa and Shastri, 2003), the larger C+/N+C+
intermediates were associated with the a isotype of
heat shock protein hsp90 (Figure 3). Several observa-
tions favor a specific association rather than a postlysis
artifact due to the inherent ‘‘stickiness’’ of abundantly
expressed heat shock proteins. First, only three of the
largest fragments out of a mixture of at least 13 N+ and
C+/N+C+ fragments present in the cells were found in
the hsp90a immunoprecipitate (Figure 2C versus Figures
3D and 3E). Second, the antigenic fragments were asso-
ciated only to hsp90a, although both hsp90a and hsp90b
are functionally equivalent in their binding to numerous
client substrates (Picard, 2002). Third, knockdown of
hsp90a by siRNA inhibited the recovery of the same set
of peptides in total cell extracts. Because the presence
of naturally processed peptides in extracts prepared by
boiling cells in formic acid does not require detergent ly-
sis, this is an independent measure of hsp90a function in
intact cells. Finally, inhibition of hsp90a or its cochaper-
one CHIP also diminished the presentation of the final
SHL8/Kb complex on the cell surface. Taken together
these findings suggest that not only do the C+/N+C+ pre-
cursors associate specifically with hsp90a but also that
this association is functionally relevant. It is important
to note that it is formally possible that our results reflect
an indirect effect of some other hsp90a-associated pro-
tein (Picard, 2002). However, given the well-established
chaperone functions of hsp90, we favor the simplest
interpretation that the interactions between the proteo-
lytic intermediates and hsp90a are direct.
A role for hsp90 in antigen processing is also consis-
tent with another study by Udono and colleagues
(Yamano et al., 2002). They found that introduction of ex-
ogenous hsp90 into the cytoplasm enhanced the pre-
sentation of the SL8/Kb complex derived from synthetic
peptides containing SL8 with N- and C-terminal flanking
residues, but not N-terminal flanking residues alone. Fur-
thermore, the enhancement in antigen presentation was
abolished by proteasome inhibitors, suggesting that the
peptide/hsp90 could serve as proteasome substrates.
Our results showing that N+C+ intermediates associate
with hsp90a extend their finding to naturally processed
antigenic precursors. In addition, we found that expres-
sion of SHL8/Kb complex was inhibited when it was
generated from cytoplasmic KOVAK precursor in theabsence of the cochaperone CHIP (Figure 7). Because
CHIP interacts with both hsp90 and hsp70 family mem-
bers and is the E3 ubiquitin ligase, it can serve as a bridge
between the hsp90-associated intermediates and their
delivery to appropriate proteases.
Intriguingly, the cell surface expression of Kb MHC I
molecules as tested by flow cytometry was comparable
to untreated cells regardless of which particular hsp90
isotype or CHIP was knocked down (data not shown).
Clearly, normal expression of hsp90a/CHIP was not es-
sential for presentation of all antigenic peptides by the
cells. For example, there was no change in the genera-
tion of the peptide recognized by 27.5Z T cell hybridoma
in cells with knockdown of hsp90a or hsp90a+b (Fig-
ure 6D). It is difficult to judge the fraction of peptides
that depends upon hsp90a association. Interestingly, in
our analysis of ER aminopeptidase associated with anti-
gen processing (ERAAP) knockout mice, we noticed that
even though loss of ERAAP significantly disrupted the
pMHC I repertoire, the surface levels of most MHC I al-
leles were w20% reduced (Hammer et al., 2006). This
is a relatively small difference compared to w90% re-
duction in TAP-deficient cells in which peptide supply
from the cytoplasm is completely abrogated (Van Kaer
et al., 1992). This discrepancy could, however, be ac-
counted for by the fact that expression of certain
pMHC I increased up to 100-fold, whereas many pMHC
I were undetectable in ERAAP-deficient cells (Hammer
et al., 2006). Thus, it is possible that in the absence of
hsp90a-dependent precursors, other hsp90a-indepen-
dent peptides may have compensated for their absence.
The discovery of distinct pools of large C+/N+C+ and
smaller N+ antigenic precursors that associate with
hsp90a or TRiC chaperones also has interesting impli-
cations for crosspresentation mechanisms that have re-
cently generated much attention as well as controversy.
Crosspresentation refers to the mechanism by which pro-
fessional APCs acquire antigenic material from other cells
that express the antigenic precursor but cannot generate
the final pMHC I (Bevan, 1976). Two recent studies have
suggested, based upon inhibition of crosspresentation
by depletion of the full-length precursors or by protea-
some inhibition, that intact proteins are the primary
source of antigenic material used for cross-presentation
in vivo (Norbury et al., 2004; Shen and Rock, 2004). The
Schumacher group found that the location of the final
peptide within the antigenic precursor determined its
crosspresentation efficiency (Wolkers et al., 2004). Yet
another study using cell lysates depleted of various cyto-
plasmic (hsp70 or hsp90) or ER chaperones (caleriticulin
or gp96) showed that material associated with any of
these chaperones could be used for crosspresentation
(Binder and Srivastava, 2005). Furthermore, cells lacking
heat shock factor 1, a transcription factor for hsps, did
not serve as an efficient source of crosspriming antigens
(Zheng and Li, 2004). The crosspresentation of the LCMV
virus-derived nucleoprotein was enhanced when virus-
infected donor cells were heat shocked and the crosspre-
sentation was inhibited by the treatment of donor cells
with geldanamycin (Basta et al., 2005). The existence of
distinct pools of proteolytic intermediates at steady state
in cells and the accumulation of large antigenic fragments
after proteasome inhibition make it likely that these stud-
ies have measured the crosspresentation potential of
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processing pathway. In this context, it should be interest-
ing to examine the crosspresentation activity of hsp90-
associated material because it contains the largest
C+/N+C+ intermediates, which are most likely to represent
the earliest events in the antigen processing pathway.
A distinct role for hsp90a, but not hsp90b, in the anti-
gen processing pathway was unexpected because
both isotypes are ubiquitously expressed in high abun-
dance and are generally considered to be equivalent in
the literature being referred to as simply hsp90 (Young
et al., 2004). Both hsp90 isotypes are capable of binding
and regulating the activity of steroid hormone receptors
and kinases involved in signaling pathways (Picard et al.,
1990; Xu and Lindquist, 1993). The hsp90 has also been
shown to function as a sink for buffering the effects of
a wide range of mutations in Drosophila and plants
(Queitsch et al., 2002). These functions are disrupted
by the pharmacological inhibitors geldanamycin, radici-
col, and their analogs. Nevertheless, recent studies have
begun to question the functional redundancy of the two
isotypes. First, homozygous hsp90b deletion in mice
caused embryonic lethality despite normal expression
of hsp90a in the affected placental cells (Voss et al.,
2000). Second, hsp90a, but not hsp90b, was identified
as a determinant of tumor invasiveness in an in vitro
model (Eustace et al., 2004). However, the molecular ba-
sis of these functional distinctions between the two iso-
types is not yet known. The sequence of hsp90 proteins
indicates the presence of an N-terminal ATPase domain
connected by a charged region to a C-terminal domain.
Both domains have been implicated in mediating chap-
erone functions, but how they bind their client substrates
is not well characterized (Scheibel et al., 1998). Given that
amino acid substitutions in the two hsp90 isotypes are
scattered throughout the length of the protein, it is pres-
ently difficult to predict the structural basis for the dis-
tinct functions of the hsp90 isotypes. Our observations
add a novel function that also distinguishes the hsp90
isotypes and places hsp90a in the early steps of the
antigen processing pathway.
Experimental Procedures
Cells
The SHL8/Kb-specific, b-galactosidase-inducible B3Z hybridoma,
27.5Z hybridoma, HeLa cell lines expressing antigen including
SHL8, Kb-L cells used as APC, and their culture conditions have
been described (Kunisawa and Shastri, 2003).
Peptide Extraction and HPLC Analysis
Peptides were extracted from 5–10 3 106 cells by boiling cells with
10% formic acid and passed through 10 kDa or 30 kDa cut-off filter
and then fractionated by reverse-phase HPLC as described (Kuni-
sawa and Shastri, 2003). Five drops/fraction were collected in flat-
bottom 96-well plates and dried in a vacuum centrifuge. The fractions
were tested for antigenic activity after treatment with trypsin alone or
trypsin plus CPB as described below. Mock injections were per-
formed between samples, and the fractions were analyzed for anti-
genic activity to ensure absence of crosscontamination.
T Cell Activation Assay
SHL8/Kb-specific B3Z responses to cells or HPLC-fractionated cell
extracts were measured as the b-galactosidase activity induced
upon ligand recognition. HPLC fractions were treated with 5 mg/ml
trypsin (Sigma-Aldrich, St Louis, MO) and/or 1 U/ml carboxypepti-
dase B (CPB; EMD Biosciences, San Diego, CA) at 37ºC for 5 hr.The B3Z (1 3 105) and Kb-L cells (4 3 104) were added to each well
and cultured overnight. The b-galactosidase activity was measured
as the absorbance at 595 nm of the cleavage product of chlorophe-
nolred b-pyranoside.
Western Blot
Cells were incubated with lysis buffer (20 mM Tris-HCl [pH 7.4], 150
mM NaCl, 0.5% NP-40, 10mM leupeptin, 1mM pepstatin, 0.3mM apor-
otinin, and 10 mM MG132) at 4ºC for 30 min followed by centrifugation
(16,0003 g, 15 min) to remove cell debris. The supernatant was sep-
arated under reducing conditions on 10% SDS-PAGE and trans-
ferred to nitrocellulose membranes. The nitrocellulose membranes
were probed with antibodies against hsp90a+b, hsc70, actin,
MDM2 (Santa Cruz Biotechnology, Santa Cruz, CA), hsp90a,
hsp90b, gp96 (Neomarkers, Fremont, CA), TRiCa (clone 84a, Stress-
Gen, Victoria, Canada), or CHIP (EMD Biosciences, La Jolla, CA).
Bands were visualized with the Enhanced Chemiluminescence
(ECL) plus kit (Amersham Biosciences, Piscataway, NJ) according
to the manufacturer’s instructions. Developed blots were exposed
to Kodak hyper film and scanned.
Immunoprecipitation
5–103 107 HeLa/KOVAK cells treated with or without 10 mM geldana-
mycin (Sigma-Aldrich) overnight were lysed in buffer (20 mM Tris-HCl
[pH 7.4], 150 mM NaCl, 0.5% NP-40, 10 mM sodium molybdate, 10
mM leupeptin, 1 mM pepstatin, 0.3 mM aporotinin, 10 mM MG132,
and 10 U/ml apyrase). After 30 min incubation at 4ºC, cell debris
was removed by centrifugation (16,0003 g, 30 min) and the superna-
tant was incubated with protein G-Sepharose (Sigma-Aldrich) for 30
min at 4ºC. After centrifugation (16,000 3 g, 1 min, 4ºC) to remove
protein G-Sepharose, the supernatant was incubated with hsp90-
specific antibody or control rabbit serum (Cappel, West Chester,
PA) immobilized on protein G-Sepharose. After 5 hr incubation at
4ºC, immunoprecipitated materials were boiled with sample buffer
for SDS-PAGE or peptides were extracted from immunoprecipitates
by boiling in acid followed by B3Z assay to measure antigenic activity.
siRNA
The target sequences for hsp90a knockdown were 50-AAAGCGUUC
AUGGAAGCUUUG-30 and 50-AAGGCUGACUUGAUCAAUAAC-30.
siRNA specific for hsp90b, Neo, and CHIP were 50-AAGGAGAUUUU
CCUUCGGGAG-30, 50-AAUGAACUGCAGGACGAGGCA-30, and 50-A
AGGCCAAGCACGACAAGTAC-30. All oligonucleotides had 30 dTdT
overhangs (Dharmacon, Lafayette, CO). The MDM2-specific siRNA
was purchased from Santa Cruz Biotechnology. 13 105 cells plated
on 6-well plates were transfected with the siRNA using oligofect-
amine according to manufacture’s instruction (Invitrogen, Carlsbad,
CA), and experiments were performed at day 4.
Acid Wash Recovery Assay
HeLa/KOVAK/Kb or HeLa/ES-SHL8/Kb cells were washed with PBS
and exposed to 500 ml of 0.131 M sodium citrate, 0.066 M sodium
phosphate (pH 3.1). After 5 min incubation, the cells were washed
with PBS twice and medium once. For T cell activation assay, cells
were fixed with 1% paraformaldehyde in PBS after the incubation
for 0, 3, 6, 9, or 10 hr. Various numbers of the fixed cells were cultured
with B3Z cells for 15 hr and then B3Z activity was measured as
described above. The amount of SHL8/Kb on the cell surface was
calculated by comparison with a standard curve using synthetic
SHL8 peptide in parallel using Kb-L cells as APC. The recovery of
SHL8/Kb expression was calculated as: ([SHL8/Kb amount in sam-
ple] 2 [SHL8/Kb in t = 0])/([SHL8/Kb in untreated cells] 2 [SHL8/Kb
in t = 0]) 3 100.
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